Zacks: Brokerages Expect Ra Pharmctl Inc (RARX) Will Announce Earnings of -$0.57 Per Share

Brokerages predict that Ra Pharmctl Inc (NASDAQ:RARX) will report ($0.57) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Ra Pharmctl’s earnings. The firm is scheduled to issue its next quarterly earnings report on Thursday, August 10th.

On average, analysts expect that Ra Pharmctl will report full year earnings of ($2.25) per share for the current year, with EPS estimates ranging from ($2.35) to ($2.14). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.99) per share, with EPS estimates ranging from ($3.47) to ($2.50). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that cover Ra Pharmctl.

Ra Pharmctl (NASDAQ:RARX) last announced its quarterly earnings results on Thursday, May 11th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.08.

RARX has been the subject of a number of research reports. Jefferies Group LLC restated a “buy” rating and issued a $25.00 price objective on shares of Ra Pharmctl in a report on Wednesday, April 26th. Zacks Investment Research upgraded shares of Ra Pharmctl from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a report on Wednesday, May 17th. Five equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus target price of $27.00.

Shares of Ra Pharmctl (NASDAQ:RARX) traded down 0.28% during midday trading on Tuesday, hitting $21.30. 179,542 shares of the stock traded hands. The company’s market cap is $480.68 million. Ra Pharmctl has a 52-week low of $12.05 and a 52-week high of $27.84. The stock has a 50-day moving average of $23.17 and a 200-day moving average of $19.70.

In related news, major shareholder Bioventures Ltd Novartis sold 9,019 shares of Ra Pharmctl stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $25.50, for a total value of $229,984.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 152,460 shares of company stock valued at $3,745,249 in the last 90 days.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. FIL Ltd purchased a new position in shares of Ra Pharmctl during the fourth quarter worth about $1,975,000. Norges Bank purchased a new position in shares of Ra Pharmctl during the fourth quarter worth about $304,000. Spark Investment Management LLC purchased a new position in shares of Ra Pharmctl during the first quarter worth about $700,000. Franklin Resources Inc. purchased a new position in shares of Ra Pharmctl during the fourth quarter worth about $5,560,000. Finally, Fred Alger Management Inc. purchased a new position in shares of Ra Pharmctl during the fourth quarter worth about $223,000. Institutional investors own 62.85% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Expect Ra Pharmctl Inc (RARX) Will Announce Earnings of -$0.57 Per Share” was first posted by WKRB News and is the sole property of of WKRB News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.wkrb13.com/markets/2229364/zacks-brokerages-expect-ra-pharmctl-inc-rarx-will-announce-earnings-of-0-57-per-share.html.

About Ra Pharmctl

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Get a free copy of the Zacks research report on Ra Pharmctl (RARX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229364/zacks-brokerages-expect-ra-pharmctl-inc-rarx-will-announce-earnings-of-0-57-per-share.html

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.